211At radiolabeled APBA-FAPI for enhanced targeted-alpha therapy of glioma

Ye, Tianzhen; Yu, Yuying; Qu, Guofeng; Ma, Huan; Shi, Shilong; Ji, Jiujian; Lyu, Jie; Yang, Yuanyou; Liu, Ning; Li, Feize

doi:10.1016/j.ejmech.2024.116919

European Journal of Medicinal Chemistry

2024

DOI: 10.1016/j.ejmech.2024.116919

|View full text |Cite

211At radiolabeled APBA-FAPI for enhanced targeted-alpha therapy of glioma

Tianzhen Ye,

Yuying Yu,

Guofeng Qu

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Strong Affinity between Astatine and Silver: An Available Approach to Anchoring ²¹¹At in Nanocarrier for Locoregional Oncotherapy

Hou,

Ye,

Qin

et al. 2024

Langmuir

View full text Add to dashboard Cite

Recently,211 At-related endoradiotherapy has emerged as an important oncotherapy strategy. Conjugating 211 At with a nanocarrier provides a vital candidate for radionuclide therapy of various malignant tumors. In this study, we proposed utilizing the intrinsically high affinity of heavy halogens and sulfhydryl compounds for metallic silver to achieve highly efficient conjugation between 211 At and Ag-based nanoparticles in a simple way.

show abstract

Strong Affinity between Astatine and Silver: An Available Approach to Anchoring ²¹¹At in Nanocarrier for Locoregional Oncotherapy

Hou,

Ye,

Qin

et al. 2024

Langmuir

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

211At radiolabeled APBA-FAPI for enhanced targeted-alpha therapy of glioma

Cited by 1 publication

References 47 publications

Strong Affinity between Astatine and Silver: An Available Approach to Anchoring ²¹¹At in Nanocarrier for Locoregional Oncotherapy

Strong Affinity between Astatine and Silver: An Available Approach to Anchoring ²¹¹At in Nanocarrier for Locoregional Oncotherapy

Contact Info

Product

Resources

About

211At radiolabeled APBA-FAPI for enhanced targeted-alpha therapy of glioma

Cited by 1 publication

References 47 publications

Strong Affinity between Astatine and Silver: An Available Approach to Anchoring 211At in Nanocarrier for Locoregional Oncotherapy

Strong Affinity between Astatine and Silver: An Available Approach to Anchoring 211At in Nanocarrier for Locoregional Oncotherapy

Contact Info

Product

Resources

About

Strong Affinity between Astatine and Silver: An Available Approach to Anchoring ²¹¹At in Nanocarrier for Locoregional Oncotherapy

Strong Affinity between Astatine and Silver: An Available Approach to Anchoring ²¹¹At in Nanocarrier for Locoregional Oncotherapy